 This study will assess the efficacy and safety of ibandronate Bondronat, administered intravenously IV or orally PO, in participants with malignant bone disease and moderate to severe pain. Participants will be randomized to receive ibandronate either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily. Pain response and Karnofsky Performance Index KPI will be measured at intervals throughout the study. The anticipated time on study treatment is 4 months and the target sample size is 150 individuals. 